All In Biotech

Drug Trial Radar · NCT01768559

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin

Last checked: Nov 20, 2026Latest source record: Jan 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 894 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

894

Actual

Start

Jan 2013

Primary completion

Dec 2014

Study completion Dec 2014

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: \- To compare lixisenatide versus insulin glulisine in terms of glycosylated hemoglobin (HbA1c) reduction and body weight change at Week 26 in type 2 diabetic participants not adequately controlled on insulin glargine ± metformin. Secondary Objectives: \- To compare the treatments/regimens on: * The percentage of participants reaching the target of HbA1c \<7% or ≤6.5%, * Body weight, * Self-Monitored Glucose profiles, * Fasting Plasma Glucose (FPG), * Post-prandial plasma glucose (PPG) /glucose excursions during a standardized meal test (subset of participants), * Daily doses of insulins, * Safety and tolerability.

Conditions

  • Type 2 Diabetes

Interventions

  • Lixisenatide (AVE0010)Drug

    Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.

  • Insulin glulisine QDDrug

    Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).

  • Insulin glulisine TIDDrug

    Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value \>5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).

  • Insulin Glargine (Mandatory background drug)Drug

    Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).

  • Metformin (Background drug)Drug

    Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c From Baseline to Week 26Time frame: Baseline, Week 26
  2. Change in Body Weight From Baseline to Week 26Time frame: Baseline, Week 26

Locations

199 sites in 18 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840043

    Sun City, Arizona

  • Investigational Site Number 840042

    Tempe, Arizona

  • Investigational Site Number 840003

    Little Rock, Arkansas

  • Investigational Site Number 840031

    La Mesa, California

  • Investigational Site Number 840005

    Mission Viejo, California

  • Investigational Site Number 840057

    Northridge, California

  • Investigational Site Number 840035

    Santa Ana, California

  • Investigational Site Number 840002

    Temecula, California

  • Investigational Site Number 840037

    Walnut Creek, California

  • Investigational Site Number 840023

    West Hills, California

  • Investigational Site Number 840041

    Denver, Colorado

  • Investigational Site Number 840012

    Miami, Florida

  • Investigational Site Number 840061

    Miami, Florida

  • Investigational Site Number 840045

    Lawrenceville, Georgia

  • Investigational Site Number 840036

    Nampa, Idaho

  • Investigational Site Number 840024

    Chicago, Illinois

  • Investigational Site Number 840009

    Evanston, Illinois

  • Investigational Site Number 840004

    Avon, Indiana

  • Investigational Site Number 840055

    Avon, Indiana

  • Investigational Site Number 840027

    Des Moines, Iowa

  • Investigational Site Number 840006

    Wichita, Kansas

  • Investigational Site Number 840047

    Lexington, Kentucky

  • Investigational Site Number 840056

    Paducah, Kentucky

  • Investigational Site Number 840022

    Marrero, Louisiana

  • Investigational Site Number 840016

    Baltimore, Maryland

  • Investigational Site Number 840017

    Rockville, Maryland

  • Investigational Site Number 840025

    Buckley, Michigan

  • Investigational Site Number 840048

    Dearborn, Michigan

  • Investigational Site Number 840026

    Kalamazoo, Michigan

  • Investigational Site Number 840049

    Las Vegas, Nevada

  • Investigational Site Number 840029

    New Hyde Park, New York

  • Investigational Site Number 840060

    Smithtown, New York

  • Investigational Site Number 840030

    Staten Island, New York

  • Investigational Site Number 840011

    Salisbury, North Carolina

  • Investigational Site Number 840028

    Fargo, North Dakota

  • Investigational Site Number 840007

    Oklahoma City, Oklahoma

  • Investigational Site Number 840021

    Pittsburgh, Pennsylvania

  • Investigational Site Number 840052

    Myrtle Beach, South Carolina

  • Investigational Site Number 840032

    Chattanooga, Tennessee

  • Investigational Site Number 840033

    Nashville, Tennessee

Showing 40 of 199 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.